UDP-003

UDP-003 is a first-in-class, specially engineered and physically synthesized cyclodextrin developed by Cyclarity Therapeutics. It is designed to selectively bind and remove 7-ketocholesterol (7KC), a toxic oxidized cholesterol that accumulates in cells and tissues with age, contributing to the formation of arterial plaques and the progression of atherosclerosis. By targeting 7KC, UDP-003 aims to rejuvenate foam cells—macrophages overloaded with lipids—restoring their phagocytic function and promoting plaque regression. This mechanism offers a disease-modifying approach distinct from traditional lipid-lowering therapies like statins, which only slow plaque accumulation. Preclinical studies have shown that UDP-003 can reverse foam cell phenotype, reduce intracellular lipid accumulation, decrease reactive oxygen species (ROS), restore efferocytosis ability in macrophages, and drive urinary excretion of 7KC. The drug has advanced into Phase 1 clinical trials for acute coronary syndrome (ACS) in Australia and is being explored for other indications such as Alzheimer's disease, Niemann-Pick disease type C, carotid stenosis, peripheral arterial disorders, coronary artery disease (CAD), non-alcoholic fatty liver disease (NAFLD), stroke recovery, and more[1][3][4][5][6][7][8][9][10].

Other names

Cyclarity novel cyclodextrin molecules for multiple aging-related diseasesCyclarity cyclodextrin derivativedimerized cyclodextrin